As the fall Healthcare Reform Stakeholders Summit concludes, the panelists spend some time highlighting the biggest issues that the healthcare industry needs to continue monitoring.
Matt Salo noted that one thing that is mostly absent in the Affordable Care Act’s legislation is something on long-term care, of which Medicaid is by far the largest payer in the country. Currently, long-term care accounts for a sizable portion of Medicaid’s budget and Salo only expects that to grow.
“It’s something that I think we should be very concerned about because, by definition, Medicaid is a low-income program,” Salo said. “And when a low-income program is your only payer of long-term care, if you want long-term care you have to impoverish yourself. And that’s what we require in this country. And I think that’s a terrible, terrible national policy.”
Margaret E. O’Kane, MHA, said that the healthcare industry needs to give up on “market fantasies” and the idea that the market will take care of it. Recent specialty drug prices have disproven that notion.
Leah Binder’s main concerns are keeping the focus on the delivery of excellent care to the patient, which requires transparency and candor. Also, she wants better alignment between employers, who often get overlooked in healthcare policy discussions, and the public sector.
Lastly, Austin Frakt, PhD, is looking forward to better discussion about cost effectiveness. He wants to be able to discuss it without panic about rationing. Currently, people are using the term value instead of cost effectiveness because of the conceptions people might draw.
“I look forward to when we can discuss it a little more openly and be more explicit about, ‘you know what? That’s not valuable,” he said. “That’s what I’m looking at for the next big frontier.”
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
BRCA-Like Classification May Be a Useful Biomarker for Olaparib Response in Ovarian Cancer
May 1st 2024Adding olaparib to maintenance therapy with bevacizumab was associated with significantly longer survival for patients with ovarian cancer whose tumors have a BRCA-like genomic profile, but not among those with non-BRCA-like tumors, a study found.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Federal Trade Commission (FTC) issued letters to 10 companies to warn them that certain drug patents were improperly listed; the US Department of Agriculture (USDA) will begin testing ground beef for bird flu particles; rural Americans are more likely to die early from 1 of the 5 leading causes of death than those who live in urban areas.
Read More
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More